H Ibsen

TL;DR: The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study as discussed by the authors is a double-blind, prospective, parallel group study designed to compare the effects of losartan with those of the beta-blocker atenolol on the reduction of cardiovascular morbidity and mortality.

TL;DR: In this article, the effect of ARBs with ACEi was compared to ACEi alone and in two trials ACEi versus ARB alone (n = 25 712) in 15 large parallel long-term multicenter double-blind clinical trials of these agents involving 138 769 participants.

TL;DR: The combination of peripheral vascular disease and hypertension is an important clinical clue for renovascular disease and examination for renal vascular disease in this population is mandatory, before treatment with angiotensin converting enzyme (ACE) inhibitors is initiated.

TL;DR: UACR predicted CEP and CV death independently of LV mass andCV death was predicted by UACR and LV mass in an additive manner after adjustment for Framingham risk score and history of CV disease.

TL;DR: In supine humans at rest, MK-421 caused a reduction in blood pressure through a fall in total peripheral resistance and an increase in arterial compliance, and baroreflex sensitivity to blood pressure increase was enhanced after MK 421, and this may explain the altered baroreceptor sensitivity.